{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:29:38Z","timestamp":1794580178379,"version":"4.9.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Spread through air spaces (STAS) is a poor prognostic pathological feature recently included as a histological factor in the ninth edition of the TNM (tumor, node, and metastasis) classification. However, its clinical significance in lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations remains unclear. Here, we aimed to evaluate the clinical significance of STAS according to EGFR mutation status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 347 patients with completely resected pathological stage 0\u2013IIIB lung adenocarcinoma who were evaluated for both STAS and EGFR mutations between 2015 and 2022. We investigated the association between clinicopathological features and STAS and analyzed its prognostic relevance based on EGFR mutation status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>STAS and EGFR mutations were present in 85 (24.5%) and 178 (51.3%) patients, respectively. In patients with EGFR-mutated lung adenocarcinoma, STAS was significantly more prevalent in those with exon 19 deletions than those with the L858R mutation (P\u00a0=\u00a0.012). STAS was significantly markedly associated with poorer recurrence-free and overall survival in patients both with (P\u00a0&amp;lt;\u00a0.001 and P\u00a0&amp;lt;\u00a0.001, respectively) and without (P\u00a0=\u00a0.003 and P\u00a0=\u00a0.023, respectively) EGFR mutations. Multivariable analysis revealed that STAS was an independent prognostic factor for recurrence-free and overall survival in patients with EGFR mutations (P\u00a0&amp;lt;\u00a0.001 and P\u00a0=\u00a0.020, respectively). However, STAS was not an independent predictor in patients without EGFR mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>STAS is a key pathological feature of lung adenocarcinoma and holds considerable clinical relevance, particularly in EGFR-mutated lung adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag129","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T11:33:20Z","timestamp":1785670400000},"page":"1395-1403","source":"Crossref","is-referenced-by-count":1,"title":["Clinical significance of spread through air spaces according to\n                    <i>EGFR<\/i>\n                    mutation status in lung adenocarcinoma"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9659-3485","authenticated-orcid":false,"given":"Asato","family":"Hashinokuchi","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, NHO Kyushu Cancer Center , 3-1-1 Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kosai","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, NHO Kyushu Cancer Center , 3-1-1 Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3098-4798","authenticated-orcid":false,"given":"Naoki","family":"Haratake","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, NHO Kyushu Cancer Center , 3-1-1 Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Fujishita","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, NHO Kyushu Cancer Center , 3-1-1 Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Shimamatsu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, NHO Kyushu Cancer Center , 3-1-1 Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Kometani","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, NHO Kyushu Cancer Center , 3-1-1 Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, NHO Kyushu Cancer Center , 3-1-1 Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Toyozawa","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, NHO Kyushu Cancer Center , 3-1-1 Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Pathology, NHO Kyushu Cancer Center , 3-1-1, Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Graduate School of Medicine, Yamaguchi University , 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5601-4749","authenticated-orcid":false,"given":"Masafumi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, NHO Kyushu Cancer Center , 3-1-1 Notame, Minami-ku, Fukuoka 811-1347 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026111309165349000_ref1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026111309165349000_ref2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2026111309165349000_ref3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"2026111309165349000_ref4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026111309165349000_ref5","doi-asserted-by":"publisher","first-page":"e2347700","DOI":"10.1001\/jamanetworkopen.2023.47700","article-title":"Biomarker testing in patients with unresectable advanced or recurrent non-small cell lung cancer","volume":"6","author":"Sakamoto","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026111309165349000_ref6","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"2026111309165349000_ref7","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"2026111309165349000_ref8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jtho.2025.06.025","article-title":"The International Association for the Study of Lung Cancer Staging Project: the impact of common molecular alterations on overall survival in NSCLC in initial analyses of the IASLC Ninth Edition Staging Database","volume":"20","author":"Carbone","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026111309165349000_ref9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jtho.2021.04.003","article-title":"Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?","volume":"16","author":"Qiao","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026111309165349000_ref10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2026111309165349000_ref11","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s12253-019-00616-1","article-title":"Prognostic impact of tumor spread through air spaces in non-small cell lung cancers: a meta-analysis including 3564 patients","volume":"25","author":"Liu","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"2026111309165349000_ref12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cllc.2021.10.004","article-title":"Meta-analysis of lobectomy and sublobar resection for stage I non-small cell lung cancer with spread through air spaces","volume":"23","author":"Li","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2026111309165349000_ref13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.athoracsur.2019.02.045","article-title":"Tumor spread through air spaces in non-small cell lung cancer: a systematic review and meta-analysis","volume":"108","author":"Chen","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2026111309165349000_ref14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jtho.2024.03.015","article-title":"The IASLC lung cancer staging project: recommendation to introduce spread through air spaces (STAS) as a histologic descriptor in the 9th edition of the TNM classification of lung cancer","volume":"19","author":"Travis","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026111309165349000_ref15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/s41591-023-02230-w","article-title":"Evolutionary characterization of lung adenocarcinoma morphology in TRACERx","volume":"29","author":"Karasaki","year":"2023","journal-title":"Nat Med"},{"key":"2026111309165349000_ref16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.lungcan.2021.01.004","article-title":"The epithelial-mesenchymal transition phenotype is associated with the frequency of tumor spread through air spaces (STAS) and a high risk of recurrence after resection of lung carcinoma","volume":"153","author":"Ikeda","year":"2021","journal-title":"Lung Cancer"},{"key":"2026111309165349000_ref17","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1016\/j.cllc.2024.12.011","article-title":"Prognostic analysis of pathological stage I lung adenocarcinoma harboring major EGFR mutations","volume":"26","author":"Takamori","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"2026111309165349000_ref18","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1158\/0008-5472.CAN-15-0989","article-title":"Ligand-independent EGFR signaling","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"2026111309165349000_ref19","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1158\/0008-5472.CAN-07-0575","article-title":"Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression","volume":"67","author":"Lo","year":"2007","journal-title":"Cancer Res"},{"key":"2026111309165349000_ref20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026111309165349000_ref21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.jtho.2020.06.001","article-title":"A grading system for invasive pulmonary adenocarcinoma: a proposal from the International Association for the Study of Lung Cancer Pathology Committee","volume":"15","author":"Moreira","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026111309165349000_ref22","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jtcvs.2018.04.126","article-title":"Computed tomography features of resected lung adenocarcinomas with spread through air spaces","volume":"156","author":"Toyokawa","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026111309165349000_ref23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.21037\/tcr-22-2593","article-title":"Advances in the prediction of spread through air spaces with imaging in lung cancer: a narrative review","volume":"12","author":"Wang","year":"2023","journal-title":"Transl Cancer Res"},{"key":"2026111309165349000_ref24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026111309165349000_ref25","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026111309165349000_ref26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.cllc.2023.02.002","article-title":"Adjuvant osimertinib vs. placebo in completely resected stage IA2-IA3 EGFR-mutated NSCLC: ADAURA2","volume":"24","author":"Tsutani","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2026111309165349000_ref27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cllc.2025.08.016","article-title":"Anaplastic lymphoma kinase rearrangement and tumor spread through air spaces is associated with worse clinical outcomes for resected stage IA lung adenocarcinoma","volume":"27","author":"Shi","year":"2026","journal-title":"Clin Lung Cancer"},{"key":"2026111309165349000_ref28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.lungcan.2018.07.020","article-title":"Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces","volume":"123","author":"Lee","year":"2018","journal-title":"Lung Cancer"},{"key":"2026111309165349000_ref29","doi-asserted-by":"publisher","first-page":"1101443","DOI":"10.3389\/fgene.2023.1101443","article-title":"Comprehensive molecular characterizations of stage I-III lung adenocarcinoma with tumor spread through air spaces","volume":"14","author":"Ye","year":"2023","journal-title":"Front Genet"},{"key":"2026111309165349000_ref30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/PAS.0000000000000409","article-title":"Prognostic impact of intra-alveolar tumor spread in pulmonary adenocarcinoma","volume":"39","author":"Warth","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2026111309165349000_ref31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JTO.0000000000000486","article-title":"Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas","volume":"10","author":"Kadota","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2026111309165349000_ref32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.athoracsur.2020.05.041","article-title":"Clinical impacts of EGFR mutation status: analysis of 5780 surgically resected lung cancer cases","volume":"111","author":"Suda","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"2026111309165349000_ref33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/jjco\/hyaf217","article-title":"Spread through alveolar space predicts recurrence in epidermal growth factor receptor-mutated pathological stage IA lung adenocarcinoma","volume":"56","author":"Hattori","year":"2026","journal-title":"Jpn J Clin Oncol"},{"key":"2026111309165349000_ref34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.lungcan.2014.12.016","article-title":"EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity","volume":"87","author":"Yang","year":"2015","journal-title":"Lung Cancer"},{"key":"2026111309165349000_ref35","doi-asserted-by":"publisher","first-page":"108596","DOI":"10.1016\/j.lungcan.2025.108596","article-title":"Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes","volume":"205","author":"Abolfathi","year":"2025","journal-title":"Lung Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/11\/1395\/70685452\/hyag129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/11\/1395\/70685452\/hyag129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:17:00Z","timestamp":1794579420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/11\/1395\/8763878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,11,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag129","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,8,18]]}}}